Distribution of prepregnancy clinical and laboratory variables according to pregnancy complication status (n = 40 pregnancies)
| Variable . | No pregnancy complication (n = 12 pregnancies, N = 6 women) . | Pregnancy complication (n = 28 pregnancies, N = 17 women) . | P* . |
|---|---|---|---|
| Demographic and clinical variables | |||
| Age at pregnancy onset (range), y | 33 (31-37) | 31 (28-35) | .055 |
| Prior history of venous thrombosis | 10 (83) | 21 (75) | .563 |
| Number of women with a prior history of venous thrombosis | 5 (83) | 12 (71) | .541 |
| Number of women with a prior history of arterial thrombosis | 0 (0) | 0 (0) | N/A |
| Prior history of pregnancy complications† | 6 (50) | 17 (61) | .530 |
| Number of women with a prior history of pregnancy complications† | 4 (67) | 9 (53) | .560 |
| Autoimmune rheumatic disease‡ | 4 (33) | 6 (21) | .435 |
| LDA alone | 0 (0) | 2 (7) | .485 |
| LMWH alone | 0 (0) | 5 (18) | .298 |
| LDA+LMWH | 10 (83) | 18 (64) | .285 |
| Laboratory variables | |||
| Rosner index | 34 (26-42) | 36 (33-47) | .043 |
| aPTT-LA, s | 81 (75-100) | 96 (82-113) | .056 |
| aCL IgM | 6.2 (1.9-23.0) | 5.3 (2.9-9.8) | .243 |
| aCL IgG, GPL | 25.8 (15.0-106.1) | 51.8 (26.3-120.0) | .198 |
| aβ2GPI IgM§ | 5.0 (2.3-44.1) | 2.9 (1.4-8.5) | .229 |
| aβ2GPI IgG, GPL§ | 41.0 (11.4-97.1) | 44.8 (10.1-100.0) | .788 |
| Triple antibody positivity§ | 4 (36) | 17 (61) | .182 |
| Variable . | No pregnancy complication (n = 12 pregnancies, N = 6 women) . | Pregnancy complication (n = 28 pregnancies, N = 17 women) . | P* . |
|---|---|---|---|
| Demographic and clinical variables | |||
| Age at pregnancy onset (range), y | 33 (31-37) | 31 (28-35) | .055 |
| Prior history of venous thrombosis | 10 (83) | 21 (75) | .563 |
| Number of women with a prior history of venous thrombosis | 5 (83) | 12 (71) | .541 |
| Number of women with a prior history of arterial thrombosis | 0 (0) | 0 (0) | N/A |
| Prior history of pregnancy complications† | 6 (50) | 17 (61) | .530 |
| Number of women with a prior history of pregnancy complications† | 4 (67) | 9 (53) | .560 |
| Autoimmune rheumatic disease‡ | 4 (33) | 6 (21) | .435 |
| LDA alone | 0 (0) | 2 (7) | .485 |
| LMWH alone | 0 (0) | 5 (18) | .298 |
| LDA+LMWH | 10 (83) | 18 (64) | .285 |
| Laboratory variables | |||
| Rosner index | 34 (26-42) | 36 (33-47) | .043 |
| aPTT-LA, s | 81 (75-100) | 96 (82-113) | .056 |
| aCL IgM | 6.2 (1.9-23.0) | 5.3 (2.9-9.8) | .243 |
| aCL IgG, GPL | 25.8 (15.0-106.1) | 51.8 (26.3-120.0) | .198 |
| aβ2GPI IgM§ | 5.0 (2.3-44.1) | 2.9 (1.4-8.5) | .229 |
| aβ2GPI IgG, GPL§ | 41.0 (11.4-97.1) | 44.8 (10.1-100.0) | .788 |
| Triple antibody positivity§ | 4 (36) | 17 (61) | .182 |
Data represent either a median (25th-75th) for continuous variables or an absolute frequency (%) for count data. Data are reported for individual pregnancies, except for “Number of women with a prior history of thrombosis” and “Number of women with a prior history of pregnancy complications,” which report data for individual women.
N/A, not applicable.
P value for a difference between pregnancies with and without complications from a linear or generalized linear regression model taking into account the dependent data structure (ie, that women could have >1 pregnancy).
Pregnancy complications were defined according to revised Sapporo criteria.1
Autoimmune rheumatic disease was defined as 4 cases of systemic lupus erythematosus and 1 case of lupus-like disease.
aß2GPI IgG/IgM antibodies missing in 1 pregnancy. Cutoffs for triple antibody positivity were defined as follows: aCL >40 GPL/MPL U/mL; aβ2GPI IgG >8 GPL/MPL U/mL.